Browse by category

CagriSema associated with significant reduction in blood pressure and reduces the proportion of patients at risk of developing heart disease

Post hoc analyses from the phase 3 REDEFINE 1 trial evaluating CagriSema, an investigational injectable combination treatment for adults with overweight or obesity, and its effects on well-known cardiovascular (CV) risk factors, has revealed that systolic blood pressure was reduced by -10.9 mmHg over 68 weeks (versus -8.8 mmHg with semaglutide 2.4 mg and -2.1 mmHg with placebo). This reduction was seen regardless of BMI (less than versus greater than or equal to 35 kg/m2). In

REDEFINE 1 trial: CagriSema results in 22.7% mean weight reduction in adults with overweight or obesity

Outcomes from Novo Nordisk's phase 3 REDEFINE 1 trial - evaluating the efficacy and safety of investigational CagriSema plus lifestyle...

Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues

Dec 19

Prescription drug monitoring needed post-MBS

Dec 17

Abdominal obesity and muscle loss increases the risk of death by 83% after age 50

Dec 15